P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study
View/ Open
Author
Lee, Seung-Yul
Jeong, Young-Hoon
Ho Yun, Kyeong
Young Cho, Jae
Gorog, Diana
Angiolillo, Dominick J.
Jin Won, Kim
Jang, Yangsoo
Attention
2299/26789
Abstract
This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.